12:59 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
19:42 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest ATF3 inhibition plus chemotherapy could help treat metastases of breast cancer. In a mouse model of breast cancer treated with paclitaxel, ATF3 knockout decreased primary tumor growth and metastatic...
14:15 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse and cell culture studies suggest inhibiting TCF3 and TCF4 could help treat squamous cell carcinoma (SCC) of the skin. In two mouse models of SCC of the skin, tumor levels of...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Analytics for ALL

With the help of Alacris Theranostics GmbH 's analytical platform for predicting treatment responses in cancer, an international research team identified new treatment options for a rare, fatal form of acute lymphoblastic leukemia (ALL). The...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC); runt-related transcription factor 3 (RUNX3)

Cancer INDICATION: Cancer; solid tumors In vitro and rodent studies suggest HDAC inhibitors that activate the tumor suppressor RUNX3 could help treat cancer. Chemical synthesis and testing in an HDAC inhibition-induced RUNX3 activation assay of...
07:00 , Oct 4, 1999 |  BioCentury  |  Tools & Techniques

First, do no harm

Gene therapy has had enough trouble demonstrating efficacy in the various indications in which it is being applied without running into concerns over safety. Thus the death of a single patient in a Phase I...